Why the Therapy/Enhancement Distinction Should Still Ground Gene Editing Policy
CRISPR has turned the customization of babies from science fiction into an imminent policy concern. Medicine has long used the distinction between therapy and enhancement to draw the line between treatment and design. Can this distinction hold up in a new age of genetic editing?